Raunatin (Raunatine)

Composition Pharmacodynamics Indications Carefully Contraindications Dosing and Administration Side effects Form release / dosage
Read on
Similar drugsTo uncover
Dosage form: & nbspcoated tablets
Composition:For one tablet:

Active component:

Raunatin (Rauwolfia alkaloids)

in terms of 100% content of the sum of alkaloids

0.002 grams

Auxiliary substances of the core:

Sugar (sucrose)

0.0346 g

Potato starch

0.0290 g

Glucose monohydrate (dextrose monohydrate)

0.0136 g

Calcium stearate

0.0008 g

Mass of the core

0.08 g

Shell accessories:

Sugar (sucrose)

0.0617012 g

Magnesium carbonate basic

(magnesium hydroxycarbonate)

0.0153066 g

Polyvinylpyrrolidone low molecular weight

medical (povidone)

0.0010564 g

Titanium dioxide

0.0009680 g

Aerosil (silicon dioxide colloidal)

0.0008880 g

Vaseline oil (paraffin liquid)

0.0000384 g

Beeswax

0.0000256 g

Talc

0.0000158 g

Shell Weight

0.08 g

Film coated tablet weight

0.16 g
Description:

Tablets are round, biconvex, covered with a white coating.

Pharmacotherapeutic group:antihypertensive agent
ATX: & nbsp
  • The amount of alkaloids Rauwolfia
    • Pharmacodynamics:

    Raunatin is the sum of alkaloids from the roots of rauwolfia, the content of which in terms of dry matter is not less than 90%. Alkaloids are represented by reserpine, serpentine, aymalin and others.

    Has antihypertensive effect and antiarrhythmic action, as well as a calming effect on the central nervous system. The latter is less pronounced than in reserpine, but the drug is not inferior to reserpine for hypotensive action.In some cases, Raunatin is tolerated better than reserpine. The hypotensive effect of the drug develops more slowly than in the reserpine.

    Pharmacokinetics:

    Well absorbed from the gastrointestinal tract, but slower than reserpine, so the hypotensive effect develops gradually. It is excreted with faeces about 60% drug, with urine - 8%. The half-life is 45-168 hours.

    Indications:

    Arterial hypertension I degree of severity.

    Contraindications:

    Hypersensitivity to the components of the drug, arterial hypotension, severe bradycardia, coronary artery insufficiency, organic myocardial lesions, aortic defects, peptic ulcer and duodenal ulcer, nephrosclerosis, depression, sugar / isomaltase deficiency, fructose intolerance, glucose-galactose malabsorption, pregnancy, the period of breastfeeding, the age of 18 years.

    Carefully:

    Cardiac ischemia; patients with diabetes mellitus and people on a diet with a reduced carbohydrate content.

    If you have any of these diseases, consult a doctor before taking the drug.

    Dosing and Administration:

    Inside, after eating. Treatment should be carried out under the supervision of a physician.

    On the first day take 1 tablet (0.002 g) at night; on the second day - 1 tablet 2 times a day; on the third day - 3 tablets.

    The maximum daily dose is 6 tablets per day. After reaching therapeutic effect (after 10-14 days), the dose is gradually reduced to 1-2 tablets per day. The maintenance dose is 1 tablet per day.

    The course of treatment - 3-4 weeks, repeated courses - on the recommendation of a doctor.

    Side effects:

    There may be allergic reactions, swelling of the mucous membrane of the nasal cavity, increased sweating, asthenia, bradycardia, pain in the heart, worsening of the course of angina, development of depression or weighting of its course, decreased libido.

    If any of the side effects listed in the manual are aggravated, or if you notice any other side effects not listed in the instructions, inform the doctor about it.

    Overdose:

    Symptoms: a marked decrease in blood pressure up to a collapse, the raised diaphoresis, the general delicacy.

    Treatment: symptomatic - gastric lavage, reception of activated carbon.With a marked decrease in blood pressure, when the patient is in a collapsed position, raise his legs; If necessary, intravenous administration of rheopolyglucin or a solution of phenylephrine, or other vasoconstrictors is indicated. There are no specific antidotes.

    Interaction:

    It can be applied simultaneously or sequentially with other antihypertensive drugs (ganglion blockers, hydrochlorothiazide, hydralazine and others).

    With caution appoint together with quinidine, guanetidine, cardiac glycosides, beta-adrenoblockers (the danger of increasing the severity of negative chrono- and dromotropic action).

    The drug is able to enhance the action of ethanol and barbiturates on the central nervous system.

    Special instructions:

    Patients with ischemic heart disease may experience an increase in angina attacks. At occurrence of pains in the field of heart it is necessary to lower a dose of Raunatinum or to interrupt treatment (for 1-3 days), to consult with the doctor.

    Before the planned surgical intervention, the drug should be stopped several days before surgery. If urgent surgical intervention is required under general anesthesia in patients,taking raunatin, premedication with atropine is necessary.

    Do not use the drug before the electropulse therapy session. The dose should be reduced gradually.

    Patients with diabetes should take into account that one tablet contains about 0.139 grams of carbohydrates (0.012 XE).

    Effect on the ability to drive transp. cf. and fur:

    During treatment with the drug, patients should refrain from driving and other potentially hazardous activities requiring increased attention and speed of psychomotor reactions.

    Form release / dosage:Coated tablets, 2 mg.
    Packaging:

    10 tablets per contour cell pack.

    3 or 5 contour mesh packages together with the instruction for use are placed in a pack of cardboard.

    Storage conditions:

    In a dry, the dark place at a temperature of no higher than 25 ° C. Keep out of the reach of children.

    Shelf life:

    3 years.

    Do not use after the expiration date.

    Terms of leave from pharmacies:On prescription
    Registration number:LP-002336
    Date of registration:23.12.2013
    Date of cancellation:2018-12-23
    The owner of the registration certificate:VIFITEH, CJSC VIFITEH, CJSC Russia
    Manufacturer: & nbsp
    Representation: & nbspVIFITEH, CJSCVIFITEH, CJSC
    Information update date: & nbsp31.01.2016
    Illustrated instructions
      Instructions
      Up